Next report date
Report period
Q1 2024
EPS estimate
−5.26MXN
Revenue estimate
2.34 BMXN
−24.77MXN
−2.37 BMXN
7.89 BMXN
101.52 M
About Intra-Cellular Therapies Inc.
Sector
CEO
Sharon L. Mates
Headquarters
New York
Website
Employees (FY)
610
Founded
2002
FIGI
BBG019ZNXRT3
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ITCI is 1251.41 MXN — it has increased by 22.61% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange INTRA-CELLUAR THERAPIES INC stocks are traded under the ticker ITCI.
INTRA-CELLUAR THERAPIES INC is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
ITCI stock is 18.77% volatile and has beta coefficient of 1.02. Check out the list of the most volatile stocks — is INTRA-CELLUAR THERAPIES INC there?
ITCI earnings for the last quarter are −4.36 MXN per share, whereas the estimation was −9.86 MXN resulting in a 55.78% surprise. The estimated earnings for the next quarter are −7.66 MXN per share. See more details about INTRA-CELLUAR THERAPIES INC earnings.
INTRA-CELLUAR THERAPIES INC revenue for the last quarter amounts to 2.20 B MXN despite the estimated figure of 2.08 B MXN. In the next quarter revenue is expected to reach 2.30 B MXN.
Yes, you can track INTRA-CELLUAR THERAPIES INC financials in yearly and quarterly reports right on TradingView.
ITCI stock has risen by 22.61% compared to the previous week, the month change is a 22.61% rise, over the last year INTRA-CELLUAR THERAPIES INC has showed a 10.19% increase.
ITCI net income for the last quarter is −485.42 M MXN, while the quarter before that showed −422.83 M MXN of net income which accounts for −14.80% change. Track more INTRA-CELLUAR THERAPIES INC financial stats to get the full picture.
Today INTRA-CELLUAR THERAPIES INC has the market capitalization of 128.43 B, it has increased by 1.02% over the last week.
No, ITCI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ITCI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INTRA-CELLUAR THERAPIES INC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 30, 2024, the company has 610.00 employees. See our rating of the largest employees — is INTRA-CELLUAR THERAPIES INC on this list?
We've gathered analysts' opinions on INTRA-CELLUAR THERAPIES INC future price: according to them, ITCI price has a max estimate of 2057.37 MXN and a min estimate of 1114.41 MXN. Read a more detailed INTRA-CELLUAR THERAPIES INC forecast: see what analysts think of INTRA-CELLUAR THERAPIES INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INTRA-CELLUAR THERAPIES INC EBITDA is −2.70 B MXN, and current EBITDA margin is −34.21%. See more stats in INTRA-CELLUAR THERAPIES INC financial statements.